Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team. Smith KY, et al. Among authors: yau l. AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2. AIDS. 2009. PMID: 19542866 Clinical Trial.
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M; KLEAN study team. Eron J Jr, et al. Among authors: yau l. Lancet. 2006 Aug 5;368(9534):476-82. doi: 10.1016/S0140-6736(06)69155-1. Lancet. 2006. PMID: 16890834 Clinical Trial.
Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
Rodriguez A, Hill-Zabala C, Sloan L, Jefferson T, Yau L, Watson M, Irlbeck D, Shaefer M. Rodriguez A, et al. Among authors: yau l. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):127-9. doi: 10.1097/01.qai.0000191999.77658.6e. J Acquir Immune Defic Syndr. 2006. PMID: 16340487 Clinical Trial. No abstract available.
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Ross L, Elion R, Lanier R, Dejesus E, Cohen C, Redfield RR, Gathe JC, Hsu RK, Yau L, Paulsen D, Ha B; COL40263 Study Team. Ross L, et al. Among authors: yau l. AIDS Res Hum Retroviruses. 2009 Jul;25(7):665-72. doi: 10.1089/aid.2008.0302. AIDS Res Hum Retroviruses. 2009. PMID: 19563238 Clinical Trial.
108 results